1. Pantoni L, Gorelick PB. A book review on Cerebral Small Vessel Disease: Cambridge University Press, Cambridge, UK, 2014; p. 371. DOI: 10.1017/CBO9781139382694  3. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9: 689–701. DOI: 10.1016/S1474-4422 (10)70104-6 
4. Charidimou A, Pantoni L, Love S. The concept of sporadic cerebral small vessel disease: A road map on key definitions and current concepts. http: //journals.sagepub.com/home/wso,2015https: //doi.org/10.1177/1747493015607485 
5. Issac TGr, Chandra SR, Christopher R et al. Cerebral Small Vessel Disease Clinical, Neuropsychological, and Radiological Phenotypes, Histopathological Correlates, and Described Genotypes: A Review. J Geriatrics 2015. http: //dx.doi.org/10.1155/2015/564870 
6. Vermeer SE, Longstreth WT, Koudstaal PJ. Silent Brain Infarcts: A Systematic Review. Lancet Neurology 2007; 6: 611–9. http: //dx.doi.org/10.1016/S1474-4422 (07)70170-9
7. Shi Y, Wardlaw JM. Update on cerebral small vessel disease: a dynamic whole-brain disease. https: //svn.bmj.com/content/1/3/83 http: //dx.doi.org/10.1136/svn-2016-000035 
8. Tsai CF, Thomas B, Sudlow CL. Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review. Neurology 2013; 81: 264–72. DOI: 10.1212/WNL.0b013e31829bfde3CrossRefPubMedGoogle Scholar 
9. Wardlaw JM, Smith EE, Biessels GJ et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12: 822–38. DOI: 10.1016/S1474-4422 
10. Issac Thg, Chandra SR, Christofer R et al. Cerebral Small Vessel Disease Clinical, Neuropsychological, and Radiological Phenotypes, Histopathological Correlates, and Described Genotypes: A Review. J Geriatrics 2015. http: //dx.doi.org/10.1155/2015/564870 
11. Kwon HM, Lynn MJ, Turan TN. Frequency, risk factors, and outcome of coexistent small vessel disease and intracranial arterial stenosis: results from the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial. JAMA Neurol 2016; 73: 36–42. DOI: 10.1001/jamaneurol.2015.3145PubMedGoogle Scholar 
12. Moran С. Cerebral small vessel disease: a review of clinical, radiological, and histopathofogical phenotypes. Int J Stroke 2012; 7. Issue 1: 36–46. DOI: 10.1111/j.1747-4949.2011.00725.x 
13. Wardlaw J, Smith E, Biessels G et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12 (8): 822–38. DOI: 10.1016/s1474-4422 (13)70124-8 
14. Duering M, Csanadi E, Gesierich B. Incident lacunes preferentially localized to the edge of white matter hyperintensities: insights into the pathophysiology of cerebral small vessel disease. Brain 2013; 136: 2717–26. DOI: 10.1161/01.STR.0000240513.00579.bfAbstract/FREE Full TextGoogle Scholar 
15. Valdes Hernandez Mdel C, Maconick LC, Munoz Maniega S. A comparison of location of acute symptomatic vs. "silent" small vessel lesions. Int J Stroke 2015; 10: 1044–50. DOI: 10.1111/ijs.12558CrossRefPubMedGoogle Scholar 
16. Schmidt R, Seiler S, Loitfelder M. Longitudinal change of small-vessel disease-related brain abnormalities. J Cereb Blood Flow Metab 2016; 36: 26–39. DOI: 10.1038/jcbfm.2015.72CrossRefPubMedGoogle Scholar 
17. Greenberg SM. Small vessels, big problems. N Engl J Med 2006; 354: 1451–3. DOI: 10.1056/NEJMp068043 
18. Charidimou A. Book review: "Cerebral small vessel disease". What’s the big deal about small vessels? Front Neurol 2015; 6: 175. DOI: 10.3389/fneur.2015.00175 
19. Patel B, Markus HS. Magnetic resonance imaging in cerebral small vessel disease and its use as a surrogate disease marker. Int J Stroke 2011; 6 (1): 47–59. https: //doi.org/10.1111/j.1747-4949.2010.00552.x 
20. Араблинский А.В., Макотрова Т.А., Трусова Н.А., Левин О.С. Нейровизуализационные маркеры церебральной микроангиопатии по данным магнитно-резонансной томографии. Russian Electronic J Radiol 2014; 1: 24–31. http: //www.rejr.ru / Arablinskij A.V., Makotrova T.A., Trusova N.A., Levin O.S. Nejrovizualizacionnye markery cerebralnoj mikroangiopatii po dannym magnitno-rezonansnoj tomografii. Russian Electronic J Radiol 2014; 1: 24–31. http: //www.rejr.ru [in Russian] 
21. Мищенко В.Н., Соколик В.В. Болезнь мелких сосудов мозга (нейрорадиологические и биохимические маркеры). Український вісник психоневрології. 2014; 4 (81). / Mishenko V.N., Sokolik V.V. Bolezn melkih sosudov mozga (nejroradiologicheskie i biohimicheskie markery). Ukrayinskij visnik psihonevrologiyi. 2014; 4 (81). [in Russian] 
22. Arboix A, Alsina M, Caballero M et al. Lacunar Infarcts: Clinical and Risk Factors in 864 Patients. J Heart Stroke 2017; 2 (3): 1023. 
23. Jain KK. The Handbook of Biomarkers. N.Y.: Humana Press, 2010; p. 492. 
24. Путилина М.В. Практическая эндотелиология. Что необходимо знать врачу-клиницисту о диагностике и коррекции дисфункции эндотелия. Справочник поликлинического врача. 2017; 3: 70–7. / Putilina M.V. Practical endotheliology. What should a clinician know about the diagnosis and correction of endothelial dysfunction? Handbook for Practitioners Doctors. 2017; 3: 70–7. [in Russian] 
25. Калын Я.Б. Психическое здоровье населения пожилого и старческого возраста (клинико-эпидемиологическое исследование). Автореф. дис. … д-ра мед. наук. М., 2001. / Kalyn Ya.B. Psihicheskoe zdorove naseleniya pozhilogo i starcheskogo vozrasta (kliniko-epidemiologicheskoe issledovanie). Avtoref. dis. … d-ra med. nauk. M., 2001. [in Russian] 
26. Путилина М.В. Тревожно-депрессивные расстройства и инсульт. Возможные этиологические и патогенетические корреляции. Журн. неврологии и психиатрии им. С.С.Корсакова. 2014; 114 (6): 86–93. / Putilina M.V. Trevozhno-depressivnye rasstrojstva i insult. Vozmozhnye etiologicheskie i patogeneticheskie korrelyacii. Zhurn. nevrologii i psihiatrii im. S.S.Korsakova. 2014; 114 (6): 86–93. [in Russian] 
27. Меркин А.Г., Кажин В.А., Комаров А.Н. и др. Профилактика цереброваскулярных заболеваний и когнитивных расстройств в психиатрической и неврологической практике (обзор литературы). Неврология, нейропсихиатрия, психосоматика. 2016; 8 (3): 95–100. https: //doi.org/10.14412/2074-2711-2016-3-95-100 / Merkin A.G., Kazhin V.A., Komarov A.N. i dr. Profilaktika cerebrovaskulyarnyh zabolevanij i kognitivnyh rasstrojstv v psihiatricheskoj i nevrologicheskoj praktike (obzor literatury). Nevrologiya, nejropsihiatriya, psihosomatika. 2016; 8 (3): 95–100. https: //doi.org/10.14412/2074-2711-2016-3-95-100 [in Russian] 
28. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurology 2013; 12 (5): 483–97. DOI: 10.1016/S1474-4422 (13)70060-7 
29. Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry 2013; 18 (9): 963–74. DOI: 10.1038/mp.2013.20 
30. Cheng W, Rolls ET, Qiu J et al. Medial reward and lateral non-reward orbitofrontal cortex circuits change in opposite directions in depression. Brain 2016; 139: 3296–309. https: //doi.org/10.1093/brain/aww255 
31. Табеева Г.Р. Когнитивные и некогнитивные расстройства у пациентов пожилого возраста, ассоциированные со стрессом. Неврология, нейропсихиатрия, психосоматика. 2015; 1: 87–93. / Tabeeva G.R. Kognitivnye i nekognitivnye rasstrojstva u pacientov pozhilogo vozrasta, associirovannye so stressom. Nevrologiya, nejropsihiatriya, psihosomatika. 2015; 1: 87–93. [in Russian] 
32. Prins ND, Van Dijk EJ, Den Heijer T. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 2005; 128 (9): 2034–41. DOI: 10.1093/brain/awh553 
33. Mazzoni M, Ferroni L, Lombardi L. Mini-Mental State Examination (MMSE): sensitivity in an Italian sample of patients with dementia. Ital J Neuro Sci 1992; 13: 323. https: //doi.org/10.1007/BF02223097 
34. Poggesi, A, Gouw A, van der Flier W. Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study. J Neurol 2014; 261: 1160. https: //doi.org/10.1007/s00415-014-7332-9 
35. Дамулин И.В., Екушева Е.В. Деменция вследствие поражения мелких церебральных сосудов: современные представления о патогенезе и терапии. Неврология, нейропсихиатрия, психосоматика. 2014; 6 (4): 94–100. https://doi.org/10.14412/2074-2711-2014-4-94-100 / Damulin I.V., Ekusheva E.V. Demenciya vsledstvie porazheniya melkih cerebralnyh sosudov: sovremennye predstavleniya o patogeneze i terapii. Nevrologiya, nejropsihiatriya, psihosomatika. 2014; 6 (4): 94–100. https://doi.org/10.14412/2074-2711-2014-4-94-100 [in Russian] 
36. Lanfranconi S, Markus HS. COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review. Stroke 2010; 41 (8): e513–e518. https: //doi.org/10.1161/STROKEAHA.110.581918
37. Tojima M, Saito S, Yamamoto Y et al. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy with a Novel NOTCH3 Cys323Trp Mutation Presenting Border-Zone Infarcts: A Case Report and Literature Review. J Stroke Cerebrovasc Dis 2016; 25 (8): e128-30. DOI: 10.1016/j.jstrokecerebrovasdis.2016.05.013 
38. Maeda S, Nakayama H, Isaka K. Familial unusual encephalopathy of Binswanger's type without hypertension. Folia Psychiatr Neurol Jpn 1976; 30: 165–77. 
39. Fukutake T, Hirayama K. Familial young-adult-onset arteriosclerotic leukoencephalopathy with alopecia and lumbago without arterialhypertension. Eur Neurol 1995; 35: 69–79. 
40. Winkler D. Hereditary systemic angiopathy (HSA) with cerebral calcifica- tions, retinopthy, progressive nephropathy, and hepatopathy. J Neurol 2008; 255: 77–8. https: //doi.org/10.1007/s10072-014-1944-9 
41. Alamowitch S, Plaisier E, Favrole P. Cerebrovascular disease related to COL4A1 mutations in HANAC syndrome. Neurology 2009; 73 (22): 1873–82. 
42. Lanfranconi S, Markus HS. COL4A1 mutations as a monogenic cause of cerebral small vessel disease: A systemic review. Stroke 2010; 41: 513–8. DOI: 10.1161/strokeaha.110.581918 
43. Politei JM, Bouhassira D et al. Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment. CNS Neurosci Ther 2016; 22 (7): 568–76. DOI: 10.1111/cns.12542 
44. Lavallee PC, Labreuche J, Faille D et al Circulating markers of endothelial dysfunction and platelet activation in patients with severe symptomatic cerebral small vessel disease. Cerebrovasc Dis 2013; 36: 131–8. DOI: 10.1159/000353671 
45. Philip BM, Wardlaw JM. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. Int J Stroke 2015; 10. Issue 4: 469–78. DOI: 10.1111/ijs.12466 
46. Blanco‐Rojas L, Arboix A, Canovas D et al. Cognitive profile in patients with a first‐ever lacunar infarct with and without silent lacunes: a comparative study. BMC Neurol 2013; 13: 203. DOI: 10.1186/1471-2377-13-203 
47. Путилина М.В. Эндотелий – мишень для новых терапевтических стратегий при сосудистых заболеваниях головного мозга. Журн. неврологии и психиатрии им. С.С.Корсакова. 2017; 10: 89–97. https: //doi.org/10.17116/jnevro2017117101 / Putilina M.V. Endotelij – mishen dlya novyh terapevticheskih strategij pri sosudistyh zabolevaniyah golovnogo mozga. Zhurn. nevrologii i psihiatrii im. S.S.Korsakova. 2017; 10: 89–97. https: //doi.org/10.17116/jnevro2017117101 [in Russian] 
48. Benavente OR, Coffey CS, Conwit R et al. Blood‐pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013; 382: 507–15. DOI: 10.1016/S0140-6736 (13)60852-1
49. Davidai G, Cotton D, Gorelick P et al. Dipyridamole‐induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. Eur J Neurol 2014; 21: 1311–7. DOI: 10.1111/ene.12484 
50. Barzegar A. Proton-Coupled Electron-Transfer Mechanism for the Radical Scavenging Activity of Cardiovascular Drug Dipyridamole. PLoS ONE 2012; 7 (6): e39660. DOI: 10.1371/journal.pone.0039660): 764–9 
51. Aktas B, Utz A, Hoenig-Liedl P. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke 2003; 34 (3): 764–9. 
52. Танашян М.М., Домашенко М.А. Применение курантила при хроническом цереброваскулярном заболевании. Атмосфера. Нервные болезни. 2005; 3: 8–11. / Tanashyan M.M., Domashenko M.A. Primenenie kurantila pri hronicheskom cerebrovaskulyarnom zabolevanii. Atmosfera. Nervnye bolezni. 2005; 3: 8–11. [in Russian] 
53. Arvin A, Campadelli Fiume G, Mocarski E et al. Human Herpesviruses: Biology, Therapy and Immunoprophylaxis. Cambridge University Press, 2007; p. 1432. 
54. Карева Е.Н. Особенности фармакологического действия и применения дипиридамола в профилактике и лечении вирусных инфекций. Consilium Medicum. 2016; 18 (12): 80–7. / Kareva E.N. Features of the pharmacological actions and the use of dipyridamole in the prevention and treatment of viral infections. Consilium Medicum. 2016; 18 (12): 80–7. [in Russian] 
55. Davidai G, Cotton D, Gorelick P. Dipyridamole‐induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. Eur J Neurol 2014; 21: 1311–7. DOI: 10.1111/ene.12484 
56. Есин Р.Г., Есин О.Р., Хайруллин И.Х. Болезнь мелких сосудов: патогенетические подтипы, возможные лечебные стратегии. Consilum Mediсum. 2016; 18 (2): 104–8. / Esin R.G., Esin O.R., Khairullin I.Kh. Small vessel disease: pathogenic subtypes and possible therapeutic strategies. Consilum Mediсum. 2016; 18 (2): 104–8. [in Russian]

________________________________________________

1. Pantoni L, Gorelick PB. A book review on Cerebral Small Vessel Disease: Cambridge University Press, Cambridge, UK, 2014; p. 371. DOI: 10.1017/CBO9781139382694 
2. Charidimou A. Book review: "Cerebral small vessel disease". What’s the big deal about small vessels? Front Neurol 2015; 6: 175. DOI: 10.3389/fneur.2015.00175 
3. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9: 689–701. DOI: 10.1016/S1474-4422 (10)70104-6 
4. Charidimou A, Pantoni L, Love S. The concept of sporadic cerebral small vessel disease: A road map on key definitions and current concepts. http: //journals.sagepub.com/home/wso,2015https: //doi.org/10.1177/1747493015607485 
5. Issac TGr, Chandra SR, Christopher R et al. Cerebral Small Vessel Disease Clinical, Neuropsychological, and Radiological Phenotypes, Histopathological Correlates, and Described Genotypes: A Review. J Geriatrics 2015. http: //dx.doi.org/10.1155/2015/564870 
6. Vermeer SE, Longstreth WT, Koudstaal PJ. Silent Brain Infarcts: A Systematic Review. Lancet Neurology 2007; 6: 611–9. http: //dx.doi.org/10.1016/S1474-4422 (07)70170-9
7. Shi Y, Wardlaw JM. Update on cerebral small vessel disease: a dynamic whole-brain disease. https: //svn.bmj.com/content/1/3/83 http: //dx.doi.org/10.1136/svn-2016-000035 
8. Tsai CF, Thomas B, Sudlow CL. Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review. Neurology 2013; 81: 264–72. DOI: 10.1212/WNL.0b013e31829bfde3CrossRefPubMedGoogle Scholar 
9. Wardlaw JM, Smith EE, Biessels GJ et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12: 822–38. DOI: 10.1016/S1474-4422 
10. Issac Thg, Chandra SR, Christofer R et al. Cerebral Small Vessel Disease Clinical, Neuropsychological, and Radiological Phenotypes, Histopathological Correlates, and Described Genotypes: A Review. J Geriatrics 2015. http: //dx.doi.org/10.1155/2015/564870 
11. Kwon HM, Lynn MJ, Turan TN. Frequency, risk factors, and outcome of coexistent small vessel disease and intracranial arterial stenosis: results from the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial. JAMA Neurol 2016; 73: 36–42. DOI: 10.1001/jamaneurol.2015.3145PubMedGoogle Scholar 
12. Moran С. Cerebral small vessel disease: a review of clinical, radiological, and histopathofogical phenotypes. Int J Stroke 2012; 7. Issue 1: 36–46. DOI: 10.1111/j.1747-4949.2011.00725.x 
13. Wardlaw J, Smith E, Biessels G et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12 (8): 822–38. DOI: 10.1016/s1474-4422 (13)70124-8 
14. Duering M, Csanadi E, Gesierich B. Incident lacunes preferentially localized to the edge of white matter hyperintensities: insights into the pathophysiology of cerebral small vessel disease. Brain 2013; 136: 2717–26. DOI: 10.1161/01.STR.0000240513.00579.bfAbstract/FREE Full TextGoogle Scholar 
15. Valdes Hernandez Mdel C, Maconick LC, Munoz Maniega S. A comparison of location of acute symptomatic vs. "silent" small vessel lesions. Int J Stroke 2015; 10: 1044–50. DOI: 10.1111/ijs.12558CrossRefPubMedGoogle Scholar 
16. Schmidt R, Seiler S, Loitfelder M. Longitudinal change of small-vessel disease-related brain abnormalities. J Cereb Blood Flow Metab 2016; 36: 26–39. DOI: 10.1038/jcbfm.2015.72CrossRefPubMedGoogle Scholar 
17. Greenberg SM. Small vessels, big problems. N Engl J Med 2006; 354: 1451–3. DOI: 10.1056/NEJMp068043 
18. Charidimou A. Book review: "Cerebral small vessel disease". What’s the big deal about small vessels? Front Neurol 2015; 6: 175. DOI: 10.3389/fneur.2015.00175 
19. Patel B, Markus HS. Magnetic resonance imaging in cerebral small vessel disease and its use as a surrogate disease marker. Int J Stroke 2011; 6 (1): 47–59. https: //doi.org/10.1111/j.1747-4949.2010.00552.x 
20. Arablinskij A.V., Makotrova T.A., Trusova N.A., Levin O.S. Nejrovizualizacionnye markery cerebralnoj mikroangiopatii po dannym magnitno-rezonansnoj tomografii. Russian Electronic J Radiol 2014; 1: 24–31. http: //www.rejr.ru [in Russian] 
21. Mishenko V.N., Sokolik V.V. Bolezn melkih sosudov mozga (nejroradiologicheskie i biohimicheskie markery). Ukrayinskij visnik psihonevrologiyi. 2014; 4 (81). [in Russian] 
22. Arboix A, Alsina M, Caballero M et al. Lacunar Infarcts: Clinical and Risk Factors in 864 Patients. J Heart Stroke 2017; 2 (3): 1023. 
23. Jain KK. The Handbook of Biomarkers. N.Y.: Humana Press, 2010; p. 492. 
24. Putilina M.V. Practical endotheliology. What should a clinician know about the diagnosis and correction of endothelial dysfunction? Handbook for Practitioners Doctors. 2017; 3: 70–7. [in Russian] 
25. Kalyn Ya.B. Psihicheskoe zdorove naseleniya pozhilogo i starcheskogo vozrasta (kliniko-epidemiologicheskoe issledovanie). Avtoref. dis. … d-ra med. nauk. M., 2001. [in Russian] 
26. Putilina M.V. Trevozhno-depressivnye rasstrojstva i insult. Vozmozhnye etiologicheskie i patogeneticheskie korrelyacii. Zhurn. nevrologii i psihiatrii im. S.S.Korsakova. 2014; 114 (6): 86–93. [in Russian] 
27. Merkin A.G., Kazhin V.A., Komarov A.N. i dr. Profilaktika cerebrovaskulyarnyh zabolevanij i kognitivnyh rasstrojstv v psihiatricheskoj i nevrologicheskoj praktike (obzor literatury). Nevrologiya, nejropsihiatriya, psihosomatika. 2016; 8 (3): 95–100. https: //doi.org/10.14412/2074-2711-2016-3-95-100 [in Russian] 
28. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurology 2013; 12 (5): 483–97. DOI: 10.1016/S1474-4422 (13)70060-7 
29. Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry 2013; 18 (9): 963–74. DOI: 10.1038/mp.2013.20 
30. Cheng W, Rolls ET, Qiu J et al. Medial reward and lateral non-reward orbitofrontal cortex circuits change in opposite directions in depression. Brain 2016; 139: 3296–309. https: //doi.org/10.1093/brain/aww255 
31. Tabeeva G.R. Kognitivnye i nekognitivnye rasstrojstva u pacientov pozhilogo vozrasta, associirovannye so stressom. Nevrologiya, nejropsihiatriya, psihosomatika. 2015; 1: 87–93. [in Russian] 
32. Prins ND, Van Dijk EJ, Den Heijer T. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 2005; 128 (9): 2034–41. DOI: 10.1093/brain/awh553 
33. Mazzoni M, Ferroni L, Lombardi L. Mini-Mental State Examination (MMSE): sensitivity in an Italian sample of patients with dementia. Ital J Neuro Sci 1992; 13: 323. https: //doi.org/10.1007/BF02223097 
34. Poggesi, A, Gouw A, van der Flier W. Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study. J Neurol 2014; 261: 1160. https: //doi.org/10.1007/s00415-014-7332-9 
35. Damulin I.V., Ekusheva E.V. Demenciya vsledstvie porazheniya melkih cerebralnyh sosudov: sovremennye predstavleniya o patogeneze i terapii. Nevrologiya, nejropsihiatriya, psihosomatika. 2014; 6 (4): 94–100. https://doi.org/10.14412/2074-2711-2014-4-94-100 [in Russian] 
36. Lanfranconi S, Markus HS. COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review. Stroke 2010; 41 (8): e513–e518. https: //doi.org/10.1161/STROKEAHA.110.581918
37. Tojima M, Saito S, Yamamoto Y et al. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy with a Novel NOTCH3 Cys323Trp Mutation Presenting Border-Zone Infarcts: A Case Report and Literature Review. J Stroke Cerebrovasc Dis 2016; 25 (8): e128-30. DOI: 10.1016/j.jstrokecerebrovasdis.2016.05.013 
38. Maeda S, Nakayama H, Isaka K. Familial unusual encephalopathy of Binswanger's type without hypertension. Folia Psychiatr Neurol Jpn 1976; 30: 165–77. 
39. Fukutake T, Hirayama K. Familial young-adult-onset arteriosclerotic leukoencephalopathy with alopecia and lumbago without arterialhypertension. Eur Neurol 1995; 35: 69–79. 
40. Winkler D. Hereditary systemic angiopathy (HSA) with cerebral calcifica- tions, retinopthy, progressive nephropathy, and hepatopathy. J Neurol 2008; 255: 77–8. https: //doi.org/10.1007/s10072-014-1944-9 
41. Alamowitch S, Plaisier E, Favrole P. Cerebrovascular disease related to COL4A1 mutations in HANAC syndrome. Neurology 2009; 73 (22): 1873–82. 
42. Lanfranconi S, Markus HS. COL4A1 mutations as a monogenic cause of cerebral small vessel disease: A systemic review. Stroke 2010; 41: 513–8. DOI: 10.1161/strokeaha.110.581918 
43. Politei JM, Bouhassira D et al. Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment. CNS Neurosci Ther 2016; 22 (7): 568–76. DOI: 10.1111/cns.12542 
44. Lavallee PC, Labreuche J, Faille D et al Circulating markers of endothelial dysfunction and platelet activation in patients with severe symptomatic cerebral small vessel disease. Cerebrovasc Dis 2013; 36: 131–8. DOI: 10.1159/000353671 
45. Philip BM, Wardlaw JM. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. Int J Stroke 2015; 10. Issue 4: 469–78. DOI: 10.1111/ijs.12466 
46. Blanco‐Rojas L, Arboix A, Canovas D et al. Cognitive profile in patients with a first‐ever lacunar infarct with and without silent lacunes: a comparative study. BMC Neurol 2013; 13: 203. DOI: 10.1186/1471-2377-13-203 
47. Putilina M.V. Endotelij – mishen dlya novyh terapevticheskih strategij pri sosudistyh zabolevaniyah golovnogo mozga. Zhurn. nevrologii i psihiatrii im. S.S.Korsakova. 2017; 10: 89–97. https: //doi.org/10.17116/jnevro2017117101 [in Russian] 
48. Benavente OR, Coffey CS, Conwit R et al. Blood‐pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013; 382: 507–15. DOI: 10.1016/S0140-6736 (13)60852-1
49. Davidai G, Cotton D, Gorelick P et al. Dipyridamole‐induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. Eur J Neurol 2014; 21: 1311–7. DOI: 10.1111/ene.12484 
50. Barzegar A. Proton-Coupled Electron-Transfer Mechanism for the Radical Scavenging Activity of Cardiovascular Drug Dipyridamole. PLoS ONE 2012; 7 (6): e39660. DOI: 10.1371/journal.pone.0039660): 764–9 
51. Aktas B, Utz A, Hoenig-Liedl P. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke 2003; 34 (3): 764–9. 
52. Tanashyan M.M., Domashenko M.A. Primenenie kurantila pri hronicheskom cerebrovaskulyarnom zabolevanii. Atmosfera. Nervnye bolezni. 2005; 3: 8–11. [in Russian] 
53. Arvin A, Campadelli Fiume G, Mocarski E et al. Human Herpesviruses: Biology, Therapy and Immunoprophylaxis. Cambridge University Press, 2007; p. 1432. 
54. Kareva E.N. Features of the pharmacological actions and the use of dipyridamole in the prevention and treatment of viral infections. Consilium Medicum. 2016; 18 (12): 80–7. [in Russian] 
55. Davidai G, Cotton D, Gorelick P. Dipyridamole‐induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. Eur J Neurol 2014; 21: 1311–7. DOI: 10.1111/ene.12484 
56. Esin R.G., Esin O.R., Khairullin I.Kh. Small vessel disease: pathogenic subtypes and possible therapeutic strategies. Consilum Mediсum. 2016; 18 (2): 104–8. [in Russian]

М.В.Путилина

ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
profput@mail.ru

________________________________________________

M.V.Putilina

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
profput@mail.ru